BioSpace News Archive

Drug Development

EIP Pharma Publishes Positive Alzheimer’s Disease Clinical Study Data with Neflamapimod

Phase 2a Results Published in Annals of Clinical and Translational Neurology Demonstrate Statistically Significant Improvement in Episodic Memory Function in Patients with Alzheimer’s Disease; Company Initiates Phase 2b (REVERSE-SD) Confirmatory Study with Neflamapimod

March 7, 2018
·
4 min read
Business

Agenus to Report Fourth Quarter and Full Year 2017 Financial Results on March 15, 2018 and Host Conference Call and Webcast

Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune checkpoint antibodies and cancer vaccines, will release its fourth quarter and full year 2017 financial results before the market opens on Thursday, March 15, 2018

March 7, 2018
·
2 min read
Drug Development

Daiichi Sankyo Initiates Phase 2 Study of DS-8201 in Patients with HER2-Expressing Advanced Colorectal Cancer

- Global phase 2 study will evaluate efficacy and safety of DS-8201 in patients with HER2-expressing advanced colorectal cancer who have received at least two prior lines of standard treatment

March 7, 2018
·
7 min read
Pharm Country

MTF Biologics and the University of Missouri Highlight Positive Clinical Results for Missouri Osteochondral Allograft Preservation System

New preservation system advances the field of osteochondral allografts, significantly increasing storage life, improving viability, and maximizing tissue used in joint repairs

March 7, 2018
·
3 min read
Business

Aevi Genomic Medicine Expands Collaboration with Kyowa Hakko Kirin

Early stage program in an ultra-orphan pediatric indication with potential to expand to additional indications post proof of concept.

March 7, 2018
·
4 min read
Business

Compugen Has Licensed Selexis’ Cell Line-Based Protein Expression Platform for the Development of Antibody-Based Therapeutics

Selexis SUREtechnology Platform™ in use for the generation of high-performance research cell banks for Compugen

March 7, 2018
·
3 min read
FDA

Orthofix Secures FDA and CE Mark Approvals for New PhysioStim Bone Growth Stimulators

Devices unveiled today at AAOS Annual Meeting in New Orleans

March 7, 2018
·
4 min read
Drug Development

Seattle Genetics Initiates New Phase 1 Study in Relapsed or Refractory Multiple Myeloma

Antibody-Drug Conjugate (ADC) SGN-CD48A Being Evaluated as Monotherapy, With Innovative Linker Technology That Highlights Continued Industry Leadership in ADCs

March 7, 2018
·
4 min read
Drug Development

BioTime Announces DSMB Approval to Proceed to Cohort 4 of the OpRegen® Clinical Trial

Continued safety from cohorts 1, 2 and 3 included in assessment by independent DSMB; Cohort 4 will focus on earlier stage dry-AMD patients; Additional functional data assessments are included in Cohort 4

March 7, 2018
·
4 min read
Policy

Vaxart Expands Intellectual Property Portfolio With U.S. Patent Allowance

Issued Claims Cover High Yield Production Process of Phase 2 Antiviral

March 7, 2018
·
4 min read